SCHEDULE 13G: Investment Firms Disclose 5.4% Stake in Sagimet Biosciences
Beneficial Ownership Report
AP11 Limited and Ascletis Pharma Inc. have jointly disclosed a 5.4% beneficial ownership stake in Sagimet Biosciences Inc.'s Series A common stock as of December 31, 2023.
Summary
- AP11 Limited, a British Virgin Islands entity, and Ascletis Pharma Inc., a Cayman Islands entity, have each reported beneficial ownership of 1,654,701 shares of Sagimet Biosciences Inc.'s Series A common stock.
- This ownership represents 5.4% of the class for each reporting person.
- The reported percentage is calculated based on 30,674,855 shares of Series A common stock outstanding as of March 5, 2025, as reported in Sagimet Biosciences Inc.'s Form 10-K filed with the SEC on March 12, 2025.
- Both AP11 Limited and Ascletis Pharma Inc. hold sole voting power and sole dispositive power over their respective 1,654,701 shares.
Sentiment
Score: 5
Explanation: The document is a factual regulatory disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding significant ownership stakes in Sagimet Biosciences Inc., offering insight into the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 12/31/2023 | Date of event which required the filing of this statement (beneficial ownership threshold met). |
| 03/05/2025 | Date as of which 30,674,855 shares of Series A common stock were outstanding, used for percentage calculation. |
| 03/12/2025 | Date Sagimet Biosciences Inc.'s Form 10-K was filed, reporting the outstanding shares. |
| 05/13/2025 | Date the Schedule 13G statement was signed by Huqin Yang, Treasurer for both reporting persons. |
Keywords
Sagimet Biosciences Inc., AP11 Limited, Ascletis Pharma Inc., Series A common stock, Beneficial ownership, Schedule 13G, SEC filing, Equity stake, Institutional investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.